Compared to chemotherapy, Navoliu monoantigen combined with ipimus was used in patients with previously untreated malignant thoracic mesothelioma to show long-lasting survival benefits.

On August 8, 2020, Pershing Meishiguibao announced today that a Phase III clinical study called CheckMate-743 confirmed that The combined Ipimu monotherapy of Navulyu monoin injections significantly improved the overall survival (OS) of patients with previously untreated, non-removable malignant thymus mesothelioma.
The shortest follow-up period of 22 months was 22 months, Navulyu monoantigenic ipimus reduced the risk of death by 26%, the patient's mid-OS was 18.1 months, and the chemotherapy group was 14.1 months (risk ratio: 0.74 (96.6% confidence interval): 0.60, 0.91;
, the two-year survival rate was 41% for patients in the Navuliyu combined Ipimu monotherapy group, compared with 27% for the chemotherapy group.
safety of navulyu mono-anti-combined Ipimu monoantigen is consistent with previously reported studies, and no new safety signals have been observed.
research data (Summary No. 3) will be presented on August 8, 2020 at 7 a.m. EST at the 2020 World Lung Cancer Congress Online Presidential Symposium hosted by the International Lung Cancer Research Association (IASLC).
Dr Paul Baas, chest oncology at Leiden University in the Netherlands and the Netherlands Cancer Institute, said: "Malignant thoracic mesothelioma is a highly aggressive cancer with a five-year survival rate of less than 10 per cent, after a number of clinical outcomes were not satisfactory.
we are now demonstrating for the first time that dual immuno combination therapy can deliver significant and long-lasting total survival benefits for all types of malignant pleural mesothelioma patients compared to chemotherapy.
based on CheckMate-743 data, Navoliu monoantigen combined with ipimal monotherapy is expected to become the new standard treatment.
" histology type is a recognized prognosis factor for malignant thoracic mesothelioma, and non-epitoriasis usually has a worse prognosis.
In the CheckMate-743 study, patients with non-epitoriasis and epithragm mesothelioma treated with Navoliu monoantigen combined with epithragm improved survival, with greater benefits observed in the subgroup of non-epidermal patients.
In the double immuno combination therapy group, the middle OS in patients with epiderm and non-epiderm was 18.7 months and 18.1 months, respectively, while in the chemotherapy group, the corresponding patients had 16.5 months and 8.8 months respectively (Epidermia HR: 0.86 (95% CI: 0.69, 1.08; Non-skin subgroup HR:0.46 (95% CI: 0.31, 0.68) ). "Following the long-lasting efficacy for patients with non-small cell lung cancer, the study data for patients with malignant thymus mesothelioma further confirm that Navulyu monoantimmune combined Ipimuma resistance is expected to alter survival expectations in patients with chest tumors," said Sabine Maier, Vice President of Clinical Development for
Perm-Meschguibo Oncology.
15 years, no new systemic treatments have been approved, and the survival time of patients with malignant thoracic mesothelioma cannot be extended.
we look forward to discussing the positive results of CheckMate-743 with global health regulators in the coming months.
" Navoliu monoantigen is a unique combination of two immuno-checkpoint inhibitors that target two different checkpoints (PD-1 and CTLA-4) to help destroy tumor cells, both of which have potential synergies: Ipiliu monoantimmunity promotes the activation and proliferation of T-cells, while Navoliu monotherapy helps existing T-cells identify tumor cells.
T cells activated by espressoma can also differentiate into memory T cells, helping to achieve a long-term anti-tumor immune response.
Note: There are currently no immuno-oncology drugs approved for the treatment of thoracic mesothelioma at Chinese mainland Regarding CheckMate-743CheckMate -743 is an open-label, multi-center, randomized, Phase III clinical study designed to To evaluate the therapeutic effect of Navuliyu monoantigenated ipimal monotherapy in patients with previously untreated malignant thymus mesothelioma (MPM; n-605) compared to standard chemotherapy (pyrethroids combined cisplatin or capa).
In this clinical study, 303 patients were treated every two weeks with Navoliu monotherapy (3 mg/kg) and once every six weeks with ipimu monotherapy (1 mg/kg) for a maximum period of 24 months, or until the onsulity or intolerance of the disease developed.
302 patients were treated with cisplatin (75 mg/m2) or capa (AUC 5) in a 21-day cycle for six cycles until the disease progressed or because it was intolerable.
end points of the trial were total survival (OS) for all randomized grouped patients, and key secondary endpoints included objective mitigation (ORR), disease control (DCR), and progression-free survival (PFS).
end points include safety, pharmacogenics, immunogenicity, and patient reporting outcomes.
about malignant thoracic mesothelioma is a rare and highly invasive malignant tumor that grows along the outside of the lungs and is highly associated with asbestos exposure.
most patients have progressed or metastasis at the time of diagnosis due to delays in diagnosis.
the prognosis of malignant thoracic mesothelioma is generally poor, and the mid-life of patients with untreated late-stage or metastatic malignant thyma mesothelioma is less than one year, with a five-year survival rate of about 10%.
.